Products are not available in all countries and may be known by different names than used on this web-page. Products, product names, indications and claims vary between countries. Always make sure to check with your local health care professional and read the actual printed package information prior to use. Information on this website might not be current and might not be an accurate reflection of current product labeling. Kerecis™ Omega3 Burn is not CE marked. Kerecis™ Omega3 Burn has been cleared by the FDA for specific indications.


There is an urgent need for new treatment options for burns. The American Burn Association estimates that 1.1 million people suffer burns annually in the United States. Approximately 45,000 patients require hospitalization. Severe burns and other major skin trauma are life- threatening injuries that require immediate surgical intervention. Frequently, this involves temporary coverage of the wounds with cadaver skin or synthetic dressings to prevent infection and dehydration because there are no full-thickness skin substitutes commercially available for the treatment of burns. Permanent closure of the wound is generally accomplished through split-thickness skin autografting after the wound bed is sufficiently stable that it will accept the transplanted tissue. Although this regimen is the standard of care for severe burns, the limited availability of and potential for pathogen transmission from cadaver skin, as well as the painful donor site wounds created during autograft surgery coupled with scarring in many instances, are serious drawbacks to this approach.

Kerecis has an ongoing commitment to advance the management of burn care. This is in part achieved through our burn research program funded by the US Department of Defense with a large clinical trial in the pipeline. A trial that will be looking critically at both the temporizing and autograft sparing effect of the product. Kerecis™ Omega3 Burn is used as an adjunct to Split Thickness Skin Grafts (STSG). After initial debridement of devitalized burn tissue the fish skin graft is inserted into the wound bed, stapled or sutured into place and secondary dressings applied to maintain the wound and graft moist. The use of the acellular fish skin graft will provide the ideal environment for wound bed preparation for STSG grafting.

Burn wounds are part of a phenomenon rather than an isolated wound. Although the healing process of the burn wound progresses in a fashion like other wounds there is a large interplay of systemic factors in this process. Normal wound healing progresses through three stages. The first is Inflammation which lasts 2 to 4 days from the time of injury. Upon injury hemostasis causes vascular constriction, and thrombus formation. Platelets in the wound release factors that recruit neutrophils and monocytes (macrophages), which in turn attract lymphocytes and fibroblasts to the site of injury. The Proliferative stage overlaps the inflammatory stage, starts at about day and lasts for several days. It is characterized by angiogenesis, collagen formation and epithelialization mediated by fibroblasts, and is complete when balance is achieved in collagen formation and its continuous breakdown by matrix metalloproteases (MMPs). The Remodeling stage is the third and last stage and can extend over a year or more. Collagen remodeling continues, fibroblasts differentiate into myofibroblasts, vascularity decreases and tissue strength increases.

The advantages of working with Kerecis™

Sales units